VR Logo

Amryt Pharma plc (AMYT) download report


Healthcare | Drugs & Pharma

Amryt Pharma plc (AMYT) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases.

IPO Date: 31-Dec-2019

CEO & Director: Dr. Joseph A. Wiley

CFO, COO & Company Sec.: Mr. Rory P. Nealon

Listing: NASDAQ: AMYT

Country: Ireland

Headquarters: Dublin,

Website: https://www.amrytpharma.com

Key Facts

Market cap: $488.75 Mln

Revenue (TTM): $233.24 Mln

Earnings (TTM): $-16.13 Mln

Cash: $102.17 Mln

Total Debt: $206.46 Mln

Insider's Holding: 0.08%

Liquidity: Low

52 Week range: $5.61 - 12.49

Shares outstanding: 64,140,000

10 Years Aggregate:

  • CFO: $-37.62 Mln
  • EBITDA: $-59.98 Mln
  • Net Profit: $-301.70 Mln

Stock Performance

Time Period Amryt Pharma (AMYT) S&P BSE Healthcare* S&P Small-Cap 600*
YTD-34.35-17.55-19.22
1 month-11.71-3.85-9.34
3 months-12.58-11.97-14.58
1 Year-43.05-15.43-17.64
3 Years--18.795.91
5 Years--9.095.64
10 Years--12.1210.10
As on 29-Jun-2022 *As on 30-Jun-2022
Year Amryt Pharma (AMYT) S&P Small-Cap 600 S&P BSE Healthcare
2021-23.7325.2720.87